Sign In
Buy OGN
$13.40
+0.0200 (+0.149%)
At Close: Jun 03, 2026
Organon (OGN) Lags Q1 Earnings Estimates
10:41am, Thursday, 04'th May 2023
Organon (OGN) came out with quarterly earnings of $1.08 per share, missing the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $1.65 per share a year ago.
Organon To Report First Quarter and Host Conference Call on May 4, 2023
07:30am, Thursday, 20'th Apr 2023
JERSEY CITY, N.J.
8 Defensive Plays as Healthcare Stocks Stumble
11:13am, Wednesday, 19'th Apr 2023
Healthcare stocks have sputtered this year after performing well in 2022. A Barron's screen has identified stocks that are poised to outperform for the rest of the year.
7 Growth Stocks That Are Trading at a Bargain Price
02:22pm, Sunday, 02'nd Apr 2023
It's too early to say the market has turned the corner, but some analysts suggest that equities could be at the beginning of a bull market. The banking crisis appears to be contained.
Francisco Garcia Parames' Cobas Funds 4th-Quater Letter
06:01pm, Wednesday, 22'nd Feb 2023
Dear Investor:
Why Shares of Organon Fell 15% Thursday
06:12pm, Thursday, 16'th Feb 2023
The company reported fourth-quarter and year-end financials.
Organon & Co (OGN) Q4 2022 Earnings Call Transcript
12:28pm, Thursday, 16'th Feb 2023
Organon & Co (NYSE:OGN ) Q4 2022 Earnings Conference Call February 16, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO & Director Matthew Walsh - EVP & CFO Conference Ca
Competition Coming For AbbVie's Blockbuster Humira
01:08am, Thursday, 16'th Feb 2023
It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
Don't Buy Viatris And Organon Just Because Of The Dividends
09:27am, Monday, 13'th Feb 2023
Viatris and Organon are what can currently be described as "deep value plays" in the pharmaceutical sector. They face largely similar challenges, but on closer inspection are quite different companies
Organon: Too Cheap To Ignore
08:05am, Tuesday, 07'th Feb 2023
Organon has a solid portfolio driven by steady established brands and fast-growing Women's Health. Management is exercising balance sheet discipline by paying down debt all while maintaining a very we
Is There Anything Organic Or Interesting About Organon?
04:01am, Tuesday, 07'th Feb 2023
Organon is a business I own - but only due to being awarded a significant number of shares, some of which I actually sold early on. I kept a stake. In this article, I'm going to follow a subscriber re
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023
07:30am, Monday, 06'th Feb 2023
JERSEY CITY, N.J.--( BUSINESS WIRE )--Organon (NYSE: OGN), a global women's healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the c
Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report?
01:33pm, Friday, 27'th Jan 2023
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Organon & Co. (OGN) CEO Kevin Ali Presents at 41st Annual J.P. Morgan Healthcare Conference (Transcript)
03:10pm, Tuesday, 10'th Jan 2023
Organon & Co. (NYSE:OGN ) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 10:30 AM ET Company Participants Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Chris Schott - J
12 Stocks Turned $10,000 To $277,126 In 12 Months
08:00am, Friday, 30'th Dec 2022
Most S&P 500 investors lost nearly 20% this year. But plenty of moneymaking stocks jumped higher.
